Abstract
INTRODUCTION
Stroke is a common neurological disorder and is a leading cause of death. More than six million cases of stroke are reported in the world annually [1] . Appro ximately 50% of the patients died and most of the survivors are left with various degree of neurological dysfunction. There is no effective treatment for restoring the neurological function of the patients to date. Recent studies in animal models of intracerebral haemorrhage demonstrated active neurogenesis in the subventricular zone leading to new neurons of phenotypes of their dead counterparts [2, 3] . Nevertheless, a majority of newly formed neurons die during the early weeks after stroke, and successful replacement only accounts for a small portion of the mature dead neurons [4] . The feasibility of using a variety of cell types including neural stem cells, embryonic stem cells, umbilical cord blood cells and mesenchymal stem cells (MSCs) to enhance reinnervation has been demonstrated in animal models [58] . The breakthrough opens cellular therapy for stroke. In clinical setting a reliable and accessible cell source is requisite. Bone marrowderived MSCs, which were noted to generate trophic factors, growth stimulants, signalling regulators and cytokines, might help promote neuroregeneration and neuro restoration after stroke via neurogenesis, angiogenesis and synaptogenesis [9] . Cellular therapy employing large numbers of ex-vivo expanded viable MSC might be a potential treatment modality to patients after stroke.
An earlier study demonstrated the feasibility and safety of infusion of autologous MSC in patients nine weeks after stroke onset [10] . In the present study we conducted a phase Ⅰ/Ⅱ randomized controlled trial of autologous bone marrowderived MSC therapy in patients one year after onset of stroke with the aim to study the longterm safety and functional efficacy of intravenous administration of MSC.
MATERIALS AND METHODS

Study design
This study is a randomized, controlled, doubleblind, Good Clinical Practice. Inclusion criteria are that patient had the onset of stroke for one year ago with stable National Institutes of Health Stroke Scale scores ≥ 7 and Glasgow Outcome Scale score of severe disability and vegetative state at one year after onset of stroke [11, 12] . Exclusion criteria are lacunar syndrome, malignant diseases, severe comorbidity, hepatic/renal dysfunction and unwillingness to participate. Patients who presented stable baseline scores indicating severe neurological disability were recruited to the study. Informed consent was obtained from all subjects in the case of vegetative state, from their next of kin. Eligible patients were randomly assigned to the treatment group and control group for autologous MSC therapy ( Figure 1 ). The study protocol was developed according to the guidelines of Consolidated Standards of Reporting Trials available online at http://www.consort statement.org/.
Radio-imaging
Computed tomography (CT) scan was conducted at onset of intracerebral haemorrhage. Haematoma volume in mL was computed by using the formula: ½ × maximal height (cm) × width (cm) × anteriorposterior diameter (cm). Magnetic resonance imaging (MRI, 1.5 Tesla) of the brain were performed on the day before the first injection of either MSC or placebos. A followup procedure was conducted on patients at 60th week upon completion of the study (Figure 1 ).
Ex vivo expansion and infusion of MSC
The procedure of MSC expansion described by Le Blanc et al [13] was adopted with minor modifications.
In brief, bone marrow aspirates from the superior iliac crest of patients under local anaesthesia were anti coagulated in 10 IU/mL preservativefree heparin (DBL, Hospira, Melbourne, Australia). Mononuclear cells were enriched by using densitygradient centrifugation in ficollhypaque with specific gravity of 1.077 g/mL (GE Healthcare BioSciences AB, Uppsala, Sweden) and cultured in lowglucose Dulbecco modified eagles' medium (Invitrogen, Life Technologies, Carlsbad, CA, United States) supplemented with 10% foetal bovine serum (Invitrogen). MSC cultures of approximately 80% in confluence were passaged using 0.05% trypsin (Invitrogen) and ex vivo expanded by subcultures in 175 cm 2 flasks.
On the day of infusion, MSC cultures were enzy matically segregated and dislodged from culture flasks by trypsin digestion, washed with phosphatebuffered saline, sieved to remove cell aggregates via 40µm filter and resuspended in 10 mL 5% normal human albumin (Hong Kong Red Cross Blood Transfusion Service) for intravenous injection in five to ten minutes. Another booster bolus of autologous MSC was prepared and administered to patient four weeks thereafter. A placebo of an equal volume of 5% normal human albumin was administered to patients being allotted to the control group. Cultures and cell processing were conducted under conditions meeting the requirements of good manufacturing practices.
Characterisation of MSC
Immunophenotyping of MSC by flow cytometry was reported elsewhere [14] . Unless stated otherwise, fluo rescenceconjugated monoclonal antibodies from Beck man Coulter were used. They were IgG1FITC, IgG1 PE, HLADRFITC, CD45FITC, CD3FITC, CD19PE, CD16FITC, CD33FITC, CD38FITC, CD34PE, CD133 PE (Miltenyi Biotec GmbH, Germany), CD29PE, CD44 FITC, CD73FITC, CD90PE, CD105PE (Serotec, United Kingdom) and CD166PE were used. At least 10000 events were acquired and signals were analysed by using the Coulter Epic XL MCL flow cytometer (Coulter, Miami, FL, United States).
Procedural details of immunofluorescence staining were described previously [15] . 
Neurological functional assessments
Patient safety and efficacy of cell therapy were evaluated during the first and second MSC infusion and thereafter at 16 th , 24 th , 36
th and 60 th week of the study ( Figure   1 ). The safety of intravenous infusion of either MSC or placebos was assessed in terms of the development of immediate or delayed adverse reactions. Immediate reactions included allergic responses (tachycardia, fever, skin eruption and leucocytosis), local complications (hematoma, local infection at the injection site), vascular obstructions (tachypnea, oliguria, peripheral vascular insufficiency, recurrence of stroke), and systemic complications (systemic infections, increased aspartate aminotransferase, alanine aminotransferase and/or blood urea nitrogen/creatinine levels). Presence of delayed adverse reaction of tumour formation was evaluated by physical examination of skin and oral mucosa and followed up with magnetic resonance ima ging (MRI), if necessary. Modified Barthel Index and Functional Independence Measure were monitored by a neurologist being blinded to group allocation and radiological data [16, 17] . Scores of Extended Glasgow Outcome Scale were also used to track the progress of disability of patients over time [12] . Stroke scale scores, vascular risk factors, medical history and demographic details were recorded.
Statistical analysis
Means, ranges and standard deviations of continuous variables of years of age, kilogram in body weight, milliliter of hematoma and bone marrow, percentages of cell counts and viability were calculated. Assuming that data were normally distributed, nonparametric Wilcoxon's rank sum test was used to compare variables derived from the treatment and control groups in the study. Paired t-test with onesided testing was used to analyse scores of modified Barthel Index, Functional Independence Measure and Extended Glasgow Outcome Scale of patients at time of assessments. Fisher's exact test was applied to examine the incidence of clinical neurological improvement between the treatment and control groups of patients. Differences between groups were regarded as significant if P ≤ 0.05.
RESULTS
Patient characteristics
We conducted a doubleblind, randomized, controlled phase Ⅰ/Ⅱ trial to examine the safety and efficacy of autologous MSC therapy in a small cohort of nine patients (four females and five males) with a mean age of 52 years (range: 4159 years) who had undergone intracerebral haemorrhage (ICH) for a year. CT scan at time of the onset demonstrated cerebral haematoma of 52 mL (1275 mL) located in the basal ganglion region of the brains of the nine patients in the study cohort. The sizes of the lesion areas were comparable between the treatment and control groups.
MSC were ex vivo expanded from a mean volume of 29 mL (1742 mL) autologous bone marrow. Patients were randomized to have two intravenous injections of autologous MSC (treatment group of MSC: n = 5 or control group of placebos: n = 4) four weeks apart. The body weight of patients in the treatment group were statistically lighter than those of the control group [treatment vs control; 54.2 kg (4260 kg) vs 67.2 kg (6472.7 kg), P = 0.03], however the years of age of both groups were comparable [treatment vs control; 53.4 (4856) vs 51.5 (4159); P = 0.64]. There was no difference between the severities of disability in terms of neurologic scores of patients assigned to both groups (data not shown).
MSC autograft
Ex vivo expanded MSC at a mean of 4 passages (18) were used for infusion. MSC up to passage8 displayed longitudinal, bipolar, spindleshaped and fibroblastlike morphology. Immunofluorescence staining demonstrated expressions of embryonic stem cell marker SSEA4, transcription factor Oct4 and neural stem cell marker Nestin; suggesting the pluripotency and neurogenesis of MSC (Figure 2 ). Flow cytometry demonstrated that they were immunophenotypically positive for CD29, CD44, CD73, CD90, CD105 and CD166 ( Figure 3A ), but negative for haematopoietic stem cell markers (CD34 and CD133), myeloid progenitor cell markers (CD33 and CD38), leucocyte markers (HLADR and CD45), Tcell marker CD3, NK cell marker CD16 and Bcell marker CD19 ( Figure 3B ). ) per kilogram body weight in two occasions except Patient NSCT02 underwent three infusions. Infused cells were immunophenotypically homogenous; HLADR, CD45, CD3, CD19, CD16, CD33, CD38, CD34 and CD133positive cells were less than 1% on average, whereas CD29, CD44, CD73, CD90, CD105 and CD166positive cells were more than 96% (Supplementary Tables 1 and 2 ). Cell viability was 94.4% (88.5%99.0%). There was no microbial growth as evident by aerobic and anaerobic cultures of 11 infusates. The control group of four patients (one female and three males) received placebos in an identical manner. No adverse reaction of acute infusion related toxicity, transient fever, complication in organs or infection was experienced by both groups of patients at time of and a day following MSC administration. There was no sign of tumour development among patients in the study cohort having monitored for a year. 
MSC infusions
Functional outcomes
Radio-imaging
Comparing MRI brain before MSC injection and at completion of the study, there was no interval change in morphology.
DISCUSSION
In the study we demonstrated the safety, feasibility and improvement of neurological outcomes of intravenous administration of autologous bone marrowderived MSC in a small cohort of nine chronic stroke patients one year after intracerebral haemorrhage through a randomized controlled doubleblinded phase Ⅰ/Ⅱ clinical trial. Despite advances in neurosurgery and contemporary medical regimes, survivors of intracerebral haemo rrhage often suffer longterm to permanent severe disabilities in terms of cognitive impairment and mo tor dysfunction. Neurological restoration remains poor. There is an imperative to develop therapeutic modalities to promote neurological recovery. Stem cell based therapy has drawn a lot of attention recently and the therapeutic efficacies of various cell types were studied [18] . Some cell types are deemed difficult for a wide application. Human neural stem cells may be the prototype, however they are not easily harvestable for transplantation unless collected from aborted foetuses or during necropsy [19, 20] . Embryonic stem cells are capable to give rise to all cell lineages, but the application to brain therapy is hindered by the risk of teratoma development and not to mention the ethical controversy [21] . Therapeutic potentials of human stem and progenitor cells from other sources; including bone marrow mononuclear cells, umbilical cord blood CD34 + cells, dental pulp stem cells, adiposederived stem cells and bone marrowderived MSC, have also been widely investigated [2226] . Previous studies indicated that only a limited number of extraneous cells had eventually implanted and integrated into neural networks of recipients. The numbers of successfully engrafted cells were far less than those lost and died to facilitate neurorestoration. Nonetheless, the implanted cells elicited the neurological recovery via indirect chaperon mechanisms of paracrine signalling of cytokines, chemokines, growth factors, trophic factors, signalling regulators and immunomodulators, which ultimately stimulated endogenous neurogenesis, angiogenesis and synaptogenesis. It is essential to investigate MSC transplantation as a cell therapy for stroke.
Shortly after the first report on the clinical trial of MSC therapy for stroke [10] , many issues arose to be resolved before MSC therapy can be safely and effectively administered to stroke patients. A plethora of clinical trials of MSC therapy for stroke, including the present study, were conducted in small cohorts of patients rendering the statistical power of safety and efficacy less valid [10, 2730] . In parallel with studies in large patient cohorts, clinical trials in small cohorts of patients would be more easily manageable and feasible to provide data for metaanalysis. The study serves the goal.
Autologous serum and platelet lysate were used to replace foetal calf serum in the supplement of basal culture media for MSC propagation in fear of the likelihood of zoonosis [28, 31] . Likewise, animal serumfree chemically modified culture media are feasible alternatives to override the likely hurdle [27] . There were concerns of loss of stemness, change of functions, senescence and transformation of prolonged cultures of human MSC, nonetheless little report on the clinical trial of human MSC at high passages is available. Honmou et al [28] reported no side effect on the administration of autologous MSC at passages ≤ 3 in stroke patients during one year of followup. More pronounced neurogenesis was observed in a rat stroke model receiving human MSC at earlier passage 2 than counterparts having human MSC at later passage 6 [32] . Bernardo and coworkers reported that longterm in vitro cultures of human bone marrowderived MSC up to passage 25 are not susceptible to malignant transformation [33] . In the study we investigated MSC at passages up to 8. There was neither morphological changes, phenotypic alterations nor growth senescence. No infusionrelated toxicity and complications were experienced by patients at time and upon completion of MSC infusion. Data of the study suggest that MSC up to passage 8 are applicable to clinical use without a compromise of safety over an observation period of a year.
It is intuitive that MSC should rest precisely in the locality of interest in the brain in order to achieve the optimal therapeutic effects. Data of clinical trials of MSC therapy demonstrate that intravenous administration is a feasible approach [10, 27, 28, 30] . However, the homing of MSC into the brain was shown to be limited and many cells were trapped into the peripheral organs especially the lungs. Alternate means of intraarterial delivery and intracranial injection using stereotactic device were also reported to be safe and feasible in human [29, 34, 35] . Nonetheless, intraarterial administration was found not superior to intravenous delivery of bone marrow mononuclear cells in a rat stroke model [36] . Both modes of cell delivery achieve comparable structural and functional outcomes in stroke animals after stem cell therapy despite the low homing efficiency.
The optimal dose of MSC applied to human is largely [10, 28, 37] . Cells of 5 × 10 7 were administered twice in the first report on the clinical trial of MSC therapy for stroke and better outcome in Barthel index was noted one year post treatment [10] . Bhasin et al [27] transplanted a mean of 56 × 10 7 MSC and reported neural plasticity. Honmou et al [28] administered intravenously 0.61.6 × 10 8 cells per patient and observed reduction of lesion size by > 20% after one week. In the study a mean of 4.6 × 10 7 MSC was administered twice and improvements of motor disability and cognitive impairment were noted. At present, available reports on clinical trials of MSC therapy suggest neurorestoration, increase of neural plasticity and reduction of lesion volume [10, 2730, 38] . Many stroke patients were noted to have lesions close to the subventricular zone [39] . The likely beneficial effects of MSC treatment might correlate with the spatial lesion not part of the subventricular zone where endogenous neurogenesis persists during adulthood and indirect chaperon effects of MSC promote endogenous neuro regeneration [40] . In the study we administered MSC to patients having severe neurological disability and presenting stable baseline scores one year after the onset of intracerebral haemorrhage to eliminate confounding attributes to the observation of MSC mediated neurological recovery.
Data of the study suggest that intravenous admini stration of autologous bone marrowderived MSC is safe and facilitate the recovery of neurological functions in patients with severe disability long after the onset of intracerebral haemorrhage. Clinical neurological improvement of patients having MSC therapy was evident compared to patients receiving placebos. MSC therapy is effective independently of other treatment courses. The work may help define criteria for future phase Ⅲ studies.
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COMMENTS
Background
This study was initiated from the randomised Phase Ⅱ from the Korean Neurologist, suggesting efficacy. Collaborating with the authors Bone Marrow Transplant Unit, the authors were able to be using autologous bone marrow mesenchymal stem cells (MSCs) of sufficient number for two interval infusion.
Research frontiers
To generate efficacy data post-stroke is important. At present there has been no effective treatment for improving neurological deficits after any stroke illnesses.
Innovations and breakthroughs
There were more data on ischaemic stroke. For brain haemorrhage, clinical data were scarce. This study showed a trend towards improvement for intracerebral haemorrhage.
Applications
The report of this work demonstrated a trend of clinical improvement on two intravenous infusions of autologous bone marrow MSC in four weeks apart.
Terminology
The work provided supportive evidence for phase Ⅲ randomized controlled trial in the future.
